New Challenge to IP Innovation
31 August 2016
Pharmaceutical Executive
Publication
Author(s):
Stephen B. Maebius
Pharmaceutical Executive
Partner Steve Maebius contributed an article to Pharmaceutical Executive, “New Challenge to IP Innovation,” on August 31, 2016. The article provided an overview of the use of Inter Partes Reviews (IPRs) in the pharmaceutical industry, for both generic and originator companies. Maebius discussed the findings of a survey that analyzed 111 IPR filings by generic drug companies against pharmaceutical patents and highlighted key considerations for originator companies.
Author(s)
Related Services
Sectors
Practice Areas
Insights
The Coming Wave of Startup M&A
04 October 2023
Foley Ignite
Startup Advisors: Why Talk to an Attorney Early On?
04 October 2023
Foley Ignite
The No Surprises Act: The Departments Proposed Another Increase to IDR Fee, Will it Stick?
03 October 2023
Health Care Law Today
Remember to Include Non-Discretionary Income When Calculating Overtime Pay Under the FLSA
02 October 2023
Labor & Employment Law Perspectives
Foley’s Historic Win in Case Against FTC Featured in Legal Press
04 October 2023
Von Bryant Comments on American Alliance for Equal Rights v. Fearless Fund
03 October 2023
NPR
Foley Represents Doceree in $35M Series B Funding
03 October 2023
Lawrence Vernaglia Comments on Recent OIG Unfavorable Advisory Opinion
02 October 2023
Report on Medicare Compliance
AI Summit New York 2023
6-7 December 2023
New York, NY
14th Annual J. Barrett Benton Health Law Conference
01 December 2023
New Orleans
American Conference Institute’s Advanced Forum on Telehealth
15-16 November 2023
New York, NY
Feeling Insecure About SECURE 2.0? A Discussion for Retirement Plan Sponsors
1 November 2023
Webinar